{"log_id": 1434090044328724607, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 0.015478, "average": 0.889659, "min": 0.68717}, "location": {"width": 98, "top": 306, "height": 34, "left": 329}, "words": "【规格】"}, {"probability": {"variance": 0.032471, "average": 0.85101, "min": 0.467508}, "location": {"width": 214, "top": 388, "height": 32, "left": 397}, "words": "1)2mg(2)4mg"}, {"probability": {"variance": 0.058179, "average": 0.856649, "min": 0.43889}, "location": {"width": 150, "top": 466, "height": 34, "left": 331}, "words": "【用】"}, {"probability": {"variance": 0.02915, "average": 0.87574, "min": 0.447333}, "location": {"width": 1008, "top": 523, "height": 59, "left": 379}, "words": "托特罗定缓释秘囊的插荐剂量为4mg,每日一次,用水将药物完整吞服据夏者的疗"}, {"probability": {"variance": 0.030762, "average": 0.889584, "min": 0.379076}, "location": {"width": 1063, "top": 583, "height": 61, "left": 326}, "words": "效和受性,该量可以减至每2本品2治疗的疗效数据尚有限(参见【临床"}, {"probability": {"variance": 0.086257, "average": 0.707084, "min": 0.356011}, "location": {"width": 91, "top": 669, "height": 27, "left": 329}, "words": "试验〗"}, {"probability": {"variance": 0.026334, "average": 0.898054, "min": 0.430559}, "location": {"width": 980, "top": 722, "height": 59, "left": 381}, "words": "刚于肝功肾功能明显减退的患,或正在使用CYP3A4强效剂的者"}, {"probability": {"variance": 0.02852, "average": 0.894113, "min": 0.376372}, "location": {"width": 1047, "top": 781, "height": 59, "left": 329}, "words": "推荐剂量为每日2n1g(参见【药理毒理】的“临床药理学和【注意事项】的“药物相作用"}, {"probability": {"variance": 0.008442, "average": 0.941865, "min": 0.750903}, "location": {"width": 146, "top": 882, "height": 34, "left": 338}, "words": "【不良反应】"}, {"probability": {"variance": 0.028737, "average": 0.849737, "min": 0.460203}, "location": {"width": 1005, "top": 939, "height": 61, "left": 386}, "words": "在Ⅱ期和期临床研究十入组患者1073例,随机分配到托罗定缓释胶(1:=537"}, {"probability": {"variance": 0.025679, "average": 0.904825, "min": 0.358503}, "location": {"width": 1060, "top": 1001, "height": 61, "left": 331}, "words": "或安慰剂组n=536)治疗剂量为2,,5或8mg日,疗程最长达15个月因为于展的各"}, {"probability": {"variance": 0.016644, "average": 0.941909, "min": 0.496824}, "location": {"width": 1063, "top": 1060, "height": 61, "left": 331}, "words": "个临床研究的条件不同,所以一个药物临床研究中观察到的不良反应发生率不能与另一个药"}, {"probability": {"variance": 0.014922, "average": 0.939919, "min": 0.526932}, "location": {"width": 1060, "top": 1120, "height": 61, "left": 333}, "words": "物临床研究中观察到的不良反发生率进行接比较,也可能不能反安临床实践中所观察到"}, {"probability": {"variance": 0.011111, "average": 0.940657, "min": 0.584222}, "location": {"width": 1060, "top": 1179, "height": 61, "left": 333}, "words": "的不灵反应发生率。但是,临床研究中得到的不良反应数为发现与药物相关的不事件和"}, {"probability": {"variance": 0.023175, "average": 0.907609, "min": 0.416632}, "location": {"width": 1060, "top": 1241, "height": 59, "left": 336}, "words": "估计不良事件发生举奠定了基训,以下数据反映的是临床对照研究中,托罗定缓释胶"}, {"probability": {"variance": 0.037706, "average": 0.858967, "min": 0.377282}, "location": {"width": 1044, "top": 1298, "height": 64, "left": 338}, "words": "囊组(n505,+mg,每当1次,震服和安慰剂组(n=507):治疗12周的不良的况"}, {"probability": {"variance": 0.013252, "average": 0.937951, "min": 0.45486}, "location": {"width": 1001, "top": 1378, "height": 61, "left": 393}, "words": "本品治疗组有52%的患省263)报告了不良事件,安剂组有4%(-247)的患"}, {"probability": {"variance": 0.02802, "average": 0.899046, "min": 0.41981}, "location": {"width": 1058, "top": 1440, "height": 59, "left": 338}, "words": "者报告了不良事件治疗报告約最常见不起事传足口干、头痛、便秘和腹痛。口千是应用"}, {"probability": {"variance": 0.022715, "average": 0.907777, "min": 0.469415}, "location": {"width": 1044, "top": 1499, "height": 59, "left": 340}, "words": "本品治疗的患者中最常见的不良事件,发生率为23.4%,安慰剂纽的发生率为7.7%。口十"}, {"probability": {"variance": 0.030889, "average": 0.880519, "min": 0.434442}, "location": {"width": 1063, "top": 1559, "height": 61, "left": 340}, "words": "便秘,视觉异常(调节功能异常)、尿留和干段病都是抗草碱剂的预翔副作用。严重零"}, {"probability": {"variance": 0.03203, "average": 0.894494, "min": 0.409801}, "location": {"width": 903, "top": 1623, "height": 54, "left": 345}, "words": "良件发生率:托特罗定缓弱胶囊纽为1.4%=7),安慰剂红为3.6%(n=18"}, {"probability": {"variance": 0.025962, "average": 0.912163, "min": 0.444912}, "location": {"width": 1008, "top": 1698, "height": 59, "left": 397}, "words": "日于不良事件导致停药的比例在治疗的最初4周最高。治疗组和安慰剂组由于不良事"}, {"probability": {"variance": 0.012732, "average": 0.927573, "min": 0.472152}, "location": {"width": 1058, "top": 1758, "height": 61, "left": 345}, "words": "件而停止治疗的患者比例相似。因口干而退出治疗的思者:治疗纽为24%=12),安慰剂"}, {"probability": {"variance": 0.041271, "average": 0.860553, "min": 0.436543}, "location": {"width": 212, "top": 1842, "height": 29, "left": 345}, "words": "组为12%m=6)a"}, {"probability": {"variance": 0.02595, "average": 0.916615, "min": 0.40052}, "location": {"width": 1003, "top": 1895, "height": 61, "left": 402}, "words": "1显示的是在为期12的山期床对照研究中用托特罗定缓释胶囊4mg:每日1次"}, {"probability": {"variance": 0.020472, "average": 0.926306, "min": 0.48618}, "location": {"width": 935, "top": 1959, "height": 57, "left": 349}, "words": "治疗的患中发生半三1%的不良事件。所报告的这些不良事件关非均和药物相关"}, {"probability": {"variance": 0.006234, "average": 0.943764, "min": 0.756652}, "location": {"width": 178, "top": 2037, "height": 34, "left": 788}, "words": "第2页:头4兀"}, {"probability": {"variance": 0.034621, "average": 0.85252, "min": 0.439906}, "location": {"width": 89, "top": 2078, "height": 29, "left": 473}, "words": "013052"}], "language": 3}